TippingPoint Biosciences Raises $4.5M to Target Pediatric Brain Cancer

The biotech startup aims to develop new treatments for deadly epigenetic drivers in pediatric brain tumors.

Mar. 31, 2026 at 12:58pm by Ben Kaplan

Got story updates? Submit your updates here. ›

A bold, abstract painting featuring sweeping geometric arcs, concentric circular patterns, and precise botanical spirals in soft, flat colors against a clean background, conceptually representing the complex epigenetic mechanisms involved in pediatric brain cancer.TippingPoint Biosciences' innovative approach to targeting hidden epigenetic drivers of pediatric brain cancer could unlock new avenues for more effective and less toxic treatments.San Francisco Today

TippingPoint Biosciences, a San Francisco-based biotech startup, has raised $4.5 million in seed funding to advance its research into new treatments for deadly pediatric brain cancers. The company is focused on developing therapies that target hidden epigenetic drivers of these aggressive tumors.

Why it matters

Pediatric brain cancer remains one of the deadliest forms of childhood cancer, with limited treatment options and poor long-term survival rates. TippingPoint's approach of targeting epigenetic mechanisms could unlock new avenues for more effective and less toxic therapies.

The details

TippingPoint Biosciences is developing small molecule drugs that aim to disrupt epigenetic regulators implicated in the growth and progression of pediatric brain tumors. The company's lead programs focus on targeting specific histone modifications and chromatin remodeling complexes that have been identified as key drivers of these deadly cancers.

  • TippingPoint Biosciences raised the $4.5 million seed round on March 31, 2026.

The players

TippingPoint Biosciences

A San Francisco-based biotech startup focused on developing new treatments for pediatric brain cancer by targeting hidden epigenetic drivers of these deadly tumors.

Got photos? Submit your photos here. ›

What’s next

TippingPoint plans to use the seed funding to advance its lead drug candidates into preclinical development and prepare for future clinical trials.

The takeaway

TippingPoint's innovative approach to targeting epigenetic mechanisms in pediatric brain cancer could lead to more effective and less toxic treatments for this devastating disease, offering new hope for young patients and their families.